We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
Read MoreHide Full Article
Eli Lilly & Company (LLY - Free Report) announced that it will soon launch an authorized generic version of its popular insulin, Humalog in the United States at a lower list price. The list price of the authorized generic version, to be called Insulin Lispro and containing an identical molecule as Humalog, will be 50% lower than the current list price of Humalog. Insulin Lispro will be available in vial and pen (KwikPen) options. The vial is priced at $137.35 while KwikPens pack of five will cost $265.20. Lilly is working to make the insulin available as quickly as possible.
Humalog brought in sales of almost $3 billion in 2018, up 5% year over year. The branded drug will remain available for those wishing to access it through existing insurance plans.
Lilly’s stock has risen 10.1% this year so far compared with a 3.9% increase for the industry.
The move comes as the three largest insulin manufacturers, Lilly, Sanofi (SNY - Free Report) and Novo Nordisk (NVO - Free Report) face increasing scrutiny for steep prices of insulins. Prices have reportedly nearly doubled in the past five years. The insulin makers have defended the high list prices by saying that they have to pay significant rebates to pharmacy benefit managers to secure market share. However, uninsured patients suffer a lot due to the high list prices of insulins.
Last week, executives from several big pharma companies including Pfizer (PFE - Free Report) , Sanofi, J&J, AbbVie and others were grilled by senators regarding high drug prices. Senators emphasized that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations. They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
Eli Lilly & Company (LLY - Free Report) announced that it will soon launch an authorized generic version of its popular insulin, Humalog in the United States at a lower list price. The list price of the authorized generic version, to be called Insulin Lispro and containing an identical molecule as Humalog, will be 50% lower than the current list price of Humalog. Insulin Lispro will be available in vial and pen (KwikPen) options. The vial is priced at $137.35 while KwikPens pack of five will cost $265.20. Lilly is working to make the insulin available as quickly as possible.
Humalog brought in sales of almost $3 billion in 2018, up 5% year over year. The branded drug will remain available for those wishing to access it through existing insurance plans.
Lilly’s stock has risen 10.1% this year so far compared with a 3.9% increase for the industry.
The move comes as the three largest insulin manufacturers, Lilly, Sanofi (SNY - Free Report) and Novo Nordisk (NVO - Free Report) face increasing scrutiny for steep prices of insulins. Prices have reportedly nearly doubled in the past five years. The insulin makers have defended the high list prices by saying that they have to pay significant rebates to pharmacy benefit managers to secure market share. However, uninsured patients suffer a lot due to the high list prices of insulins.
Last week, executives from several big pharma companies including Pfizer (PFE - Free Report) , Sanofi, J&J, AbbVie and others were grilled by senators regarding high drug prices. Senators emphasized that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations. They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection.
Lilly currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>